Active Filter(s):
Details:
The partnership between Appili and AiPharma will include the formation of a joint scientific committee to further coordinate clinical and regulatory activities for global development of Avigan®/Reeqonus™ (favipiravir), a broad-spectrum oral antiviral.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Appili Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 29, 2021